Peripheral blood blast clearance is an independent prognostic factor for survival and response to acute myeloid leukemia induction chemotherapy (Q42365051)

From Wikidata

Jump to navigation Jump to search

scientific article published on 30 July 2016

Language	Label	Description	Also known as
English	Peripheral blood blast clearance is an independent prognostic factor for survival and response to acute myeloid leukemia induction chemotherapy	scientific article published on 30 July 2016

Statements

scholarly article

1 reference

Europe PubMed Central

28 October 2017

Peripheral blood blast clearance is an independent prognostic factor for survival and response to acute myeloid leukemia induction chemotherapy (English)

1 reference

Europe PubMed Central

28 October 2017

acute myeloid leukemia

1 reference

based on heuristic

inferred from title

Nicholas J. Short

object named as

Nicholas J Short

1

0 references

Hagop Kantarjian

18

object named as

Hagop Kantarjian

1 reference

Europe PubMed Central

28 October 2017

Jorge Eduardo Cortes

14

object named as

Jorge Cortes

1 reference

Europe PubMed Central

28 October 2017

13

object named as

Tapan Kadia

1 reference

Europe PubMed Central

28 October 2017

16

object named as

Farhad Ravandi

1 reference

Europe PubMed Central

28 October 2017

Alfonso Quintas-Cardama

11

object named as

Alfonso Quintas-Cardama

1 reference

Europe PubMed Central

28 October 2017

17

object named as

Elias Jabbour

1 reference

Europe PubMed Central

28 October 2017

6

object named as

Sherry Pierce

1 reference

Europe PubMed Central

28 October 2017

Guillermo Garcia-Manero

15

object named as

Guillermo Garcia-Manero

1 reference

Europe PubMed Central

28 October 2017

Marina Konopleva

12

object named as

Marina Konopleva

1 reference

Europe PubMed Central

28 October 2017

Michael Andreeff

19

object named as

Michael Andreeff

1 reference

Europe PubMed Central

28 October 2017

7

object named as

Mark Brandt

1 reference

Europe PubMed Central

28 October 2017

8

object named as

Abhishek Maiti

1 reference

Europe PubMed Central

28 October 2017

10

object named as

Kiran Naqvi

1 reference

Europe PubMed Central

28 October 2017

Christopher B Benton

2

object named as

Christopher B Benton

1 reference

Europe PubMed Central

28 October 2017

author name string

Hsiang-Chun Chen

3

1 reference

Europe PubMed Central

28 October 2017

Peng Qiu

4

1 reference

Europe PubMed Central

28 October 2017

Lisa Gu

5

1 reference

Europe PubMed Central

28 October 2017

Taejin L Min

9

1 reference

Europe PubMed Central

28 October 2017

publication date

30 July 2016

1 reference

Europe PubMed Central

28 October 2017

American Journal of Hematology

1 reference

Europe PubMed Central

28 October 2017

91

1 reference

Europe PubMed Central

28 October 2017

12

1 reference

Europe PubMed Central

28 October 2017

1221-1226

1 reference

Europe PubMed Central

28 October 2017

Clinical significance of day 5 peripheral blast clearance rate in the evaluation of early treatment response and prognosis of patients with acute myeloid leukemia

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5118152

29 May 2018

The clinical significance of negative flow cytometry immunophenotypic results in a morphologically scored positive bone marrow in patients following treatment for acute myeloid leukemia

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5118152

29 May 2018

Prognostic and therapeutic implications of early treatment response assessment in acute myeloid leukemia

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5118152

29 May 2018

Differential impact of allelic ratio and insertion site in FLT3-ITD-positive AML with respect to allogeneic transplantation

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5118152

29 May 2018

Management of patients with cytogenetically normal acute myeloid leukemia who have neither favorable nor unfavorable markers

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5118152

29 May 2018

Prognostic significance of NPM1 mutations in acute myeloid leukemia: A meta-analysis

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5118152

29 May 2018

Final report of phase II study of sorafenib, cytarabine and idarubicin for initial therapy in younger patients with acute myeloid leukemia

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5118152

29 May 2018

Prognostic factors for acute myeloid leukaemia in adults--biological significance and clinical use.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5118152

29 May 2018

Prognostic impact of day 15 blast clearance in risk-adapted remission induction chemotherapy for younger patients with acute myeloid leukemia: long-term results of the multicenter prospective LAM-2001 trial by the GOELAMS study group

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5118152

29 May 2018

Hematopoietic stem cell transplantation for acute myeloid leukemia: to whom, when, and how.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5118152

29 May 2018

Clofarabine, idarubicin, and cytarabine (CIA) as frontline therapy for patients ≤60 years with newly diagnosed acute myeloid leukemia

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5118152

29 May 2018

Management of AML: who do we really cure?

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5118152

29 May 2018

Phase IB study of the FLT3 kinase inhibitor midostaurin with chemotherapy in younger newly diagnosed adult patients with acute myeloid leukemia

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5118152

29 May 2018

Phase II trial of vorinostat with idarubicin and cytarabine for patients with newly diagnosed acute myelogenous leukemia or myelodysplastic syndrome

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5118152

29 May 2018

Chemotherapy for patients with acute myeloid leukemia in first remission

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5118152

29 May 2018

Phase I/II study of combination therapy with sorafenib, idarubicin, and cytarabine in younger patients with acute myeloid leukemia

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5118152

29 May 2018

Diagnosis and management of acute myeloid leukemia in adults: recommendations from an international expert panel, on behalf of the European LeukemiaNet

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5118152

29 May 2018

Revised recommendations of the International Working Group for Diagnosis, Standardization of Response Criteria, Treatment Outcomes, and Reporting Standards for Therapeutic Trials in Acute Myeloid Leukemia

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5118152

29 May 2018

Early blast clearance by remission induction therapy is a major independent prognostic factor for both achievement of complete remission and long-term outcome in acute myeloid leukemia: data from the German AML Cooperative Group (AMLCG) 1992 Trial

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5118152

29 May 2018

Evaluation of survival data and two new rank order statistics arising in its consideration

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5118152

29 May 2018

Laboratory models: some historical perspective.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5118152

29 May 2018

Prospective comparison of early bone marrow evaluation on day 5 versus day 14 of the "3 + 7" induction regimen for acute myeloid leukemia.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5118152

17 August 2018

Comprehensive analysis of genetic alterations and their prognostic impacts in adult acute myeloid leukemia patients

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5118152

17 August 2018

Rapid rate of peripheral blood blast clearance accurately predicts complete remission in acute myeloid leukemia

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5118152

17 August 2018

Randomized comparison of fixed-schedule versus response-oriented individualized induction therapy and use of ubenimex during and after consolidation therapy for elderly patients with acute myeloid leukemia: the JALSG GML200 Study.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5118152

17 August 2018

Day 14 bone marrow biopsy in predicting complete remission and survival in acute myeloid leukemia.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5118152

17 August 2018

Early peripheral blood blast clearance during induction chemotherapy for acute myeloid leukemia predicts superior relapse-free survival

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5118152

17 August 2018

Risk-adapted induction and consolidation therapy in adults with de novo AML aged </= 60 years: results of a prospective multicenter trial

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5118152

17 August 2018

Bone marrow aspirate on the 14th day of induction treatment as a prognostic tool in de novo adult acute myeloid leukemia.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5118152

17 August 2018

Nonparametric Estimation from Incomplete Observations

1 reference

https://api.crossref.org/works/10.1002%2FAJH.24500

21 January 2018

Clinical application and proposal for modification of the International Working Group (IWG) response criteria in myelodysplasia

1 reference

https://api.crossref.org/works/10.1002%2FAJH.24500

21 January 2018

In vivo determination of the fractional kill of human tumor cells by chemotherapeutic agents

1 reference

https://pubmed.ncbi.nlm.nih.gov/27474808

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Double induction strategy for acute myeloid leukemia: the effect of high-dose cytarabine with mitoxantrone instead of standard-dose cytarabine with daunorubicin and 6-thioguanine: a randomized trial by the German AML Cooperative Group

1 reference

https://pubmed.ncbi.nlm.nih.gov/27474808

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

The early reduction of leukemic blasts in bone marrow on day 6 of induction treatment is predictive for complete remission rate and survival in adult acute myeloid leukemia; the results of multicenter, prospective Polish Adult Leukemia Group study

1 reference

https://pubmed.ncbi.nlm.nih.gov/27474808

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Clearance of leukaemic blasts from peripheral blood during standard induction treatment predicts the bone marrow response in acute myeloid leukaemia: a pilot study

1 reference

https://pubmed.ncbi.nlm.nih.gov/27474808

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Early clearance of peripheral blasts measured by flow cytometry during the first week of AML induction therapy as a new independent prognostic factor: a GOELAMS study

1 reference

https://pubmed.ncbi.nlm.nih.gov/27474808

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Early clearance of peripheral blood blasts predicts response to induction chemotherapy in acute myeloid leukemia

1 reference

https://pubmed.ncbi.nlm.nih.gov/27474808

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.1002/AJH.24500

1 reference

Europe PubMed Central

28 October 2017

1 reference

Europe PubMed Central

28 October 2017

1 reference

Europe PubMed Central

28 October 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q42365051&oldid=2117034480"